WAVE Life Sciences (NASDAQ:WVE) Price Target Lowered to $23.00 at Mizuho

WAVE Life Sciences (NASDAQ:WVE) had its target price reduced by research analysts at Mizuho from $27.00 to $23.00 in a research note issued to investors on Tuesday,Benzinga reports. The firm presently has an “outperform” rating on the stock. Mizuho’s price target would suggest a potential upside of 290.03% from the company’s previous close.

A number of other equities research analysts have also recently commented on WVE. Truist Financial initiated coverage on shares of WAVE Life Sciences in a report on Wednesday, April 29th. They issued a “buy” rating and a $15.00 price target on the stock. Wall Street Zen downgraded WAVE Life Sciences from a “hold” rating to a “strong sell” rating in a research report on Saturday. Weiss Ratings restated a “sell (d-)” rating on shares of WAVE Life Sciences in a research note on Friday, July 17th. Citigroup dropped their price target on WAVE Life Sciences from $24.00 to $19.00 and set a “buy” rating on the stock in a research report on Friday. Finally, B. Riley Financial decreased their price objective on WAVE Life Sciences from $31.00 to $22.00 and set a “buy” rating for the company in a report on Friday. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, WAVE Life Sciences presently has an average rating of “Moderate Buy” and an average target price of $22.53.

WAVE Life Sciences Stock Up 2.7%

WVE stock traded up $0.16 during midday trading on Tuesday, hitting $5.90. The company’s stock had a trading volume of 1,070,976 shares, compared to its average volume of 3,878,251. The stock has a market cap of $1.16 billion, a price-to-earnings ratio of -5.41 and a beta of -1.26. The stock’s 50-day moving average price is $5.96 and its 200 day moving average price is $8.88. WAVE Life Sciences has a 1 year low of $5.02 and a 1 year high of $21.73.

WAVE Life Sciences (NASDAQ:WVE) last released its earnings results on Thursday, July 30th. The company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.04). WAVE Life Sciences had a negative return on equity of 50.36% and a negative net margin of 309.73%.The business had revenue of $2.27 million for the quarter, compared to the consensus estimate of $7.45 million. As a group, equities analysts forecast that WAVE Life Sciences will post -1.12 earnings per share for the current fiscal year.

Hedge Funds Weigh In On WAVE Life Sciences

Large investors have recently made changes to their positions in the stock. GSK plc purchased a new stake in WAVE Life Sciences during the 4th quarter worth about $310,177,000. Adage Capital Partners GP L.L.C. boosted its position in shares of WAVE Life Sciences by 20.0% in the second quarter. Adage Capital Partners GP L.L.C. now owns 15,016,500 shares of the company’s stock valued at $97,607,000 after acquiring an additional 2,500,000 shares during the period. Price T Rowe Associates Inc. MD increased its holdings in WAVE Life Sciences by 83.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 7,407,372 shares of the company’s stock worth $125,927,000 after acquiring an additional 3,362,880 shares during the period. Darwin Global Management Ltd. purchased a new position in shares of WAVE Life Sciences during the 4th quarter valued at $125,168,000. Finally, Federated Hermes Inc. raised its position in shares of WAVE Life Sciences by 26.5% in the fourth quarter. Federated Hermes Inc. now owns 4,744,520 shares of the company’s stock worth $80,657,000 after buying an additional 993,827 shares in the last quarter. 89.73% of the stock is owned by institutional investors.

Key WAVE Life Sciences News

Here are the key news stories impacting WAVE Life Sciences this week:

• Positive Sentiment: WAVE said its management team will participate in two investor conferences in August. The presentations could provide additional visibility into the company’s RNA-medicine pipeline and clinical development plans, potentially giving investors new information on future catalysts. Wave Life Sciences to Present at Upcoming Investor Conferences
• Positive Sentiment: HC Wainwright raised its Q3 2026 EPS forecast to a loss of $0.29 from $0.30 and its Q4 forecast to a loss of $0.28 from $0.29. The firm maintained a Buy rating, indicating continued confidence in WAVE’s longer-term opportunity despite ongoing losses. HC Wainwright estimates and rating
• Neutral Sentiment: Although the near-term EPS estimates improved, WAVE is still expected to remain unprofitable, with consensus full-year EPS of approximately negative $1.12. The company’s recent results also showed a $0.34 quarterly loss and revenue of $2.27 million, below the $7.45 million consensus estimate, underscoring its financial and execution risks.
• Negative Sentiment: HC Wainwright reduced its FY2026 EPS estimate to a loss of $1.05 from $1.01 and lowered estimates for FY2027 through FY2030. The revisions imply slower progress toward profitability than previously expected, even though the analyst retained its Buy rating. HC Wainwright long-term EPS estimates
• Negative Sentiment: Wedbush cut its WAVE price target to $12, while Citigroup reduced its target to $19. The lower targets may weigh on sentiment, though both remain above the stock’s recent trading level and the reports did not indicate a change in the company’s underlying clinical outlook. Wedbush cuts WAVE price target Citigroup cuts WAVE price target

About WAVE Life Sciences

WAVE Life Sciences is a clinical-stage genetic medicines company focused on the discovery and development of stereopure oligonucleotide therapies designed to address serious diseases with high unmet medical need. Leveraging proprietary chemistry and precision synthesis, WAVE engineers drug candidates with defined stereochemistry to optimize potency, safety and manufacturability. This approach aims to enhance target specificity and improve therapeutic profiles compared with traditional oligonucleotide medicines.

The company’s pipeline includes programs in neuromuscular disorders such as Duchenne muscular dystrophy and neurodegenerative conditions including Huntington’s disease, as well as early-stage cardiovascular and liver indications.